Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 181–216
- Headlines
- 235
- Sources here
- 15
- Companies here
- 11
Current section
Mexico Drug Manufacturers - General news
Chronological news
Earlier headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …
ABBV
main company
Sharemaestro market context
Trend signal active
52 weeks +8.3%
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …
Sharemaestro market context Price above Trend Line 52 weeks -15.6%Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …
PFE
main company
Sharemaestro market context
Price above Trend Line
52 weeks -2.9%
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …
AZN1N
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -3.8% · Next-week setup negative 17.1%
Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …
JNJ
main company
Sharemaestro market context
Trend signal active
52 weeks +32.5%
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …
Sharemaestro market context Trend signal started 52 weeks +23.9%NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …
PFE
mentioned
Sharemaestro market context
Price above Trend Line
52 weeks -2.9%
Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half …
BAYNN
mentioned
Sharemaestro market context
Price above Trend Line
52 weeks +47.4% · Next-week setup negative 19.6%